VERO Biotech competitors

Michael Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, Ben Franklin Technology Partners and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.

Biopharmaceutical CEO and industry advisor with +33 years of experience across global geographies, most recently at industry giant UCB Biopharmaceutical. Currently Chief Executive Officer and Board member, CorMedix Inc. a publically traded US company, and Board Member at Poxel Pharma, a French publically traded Biotech company.

Paula Brown Stafford is a biopharmaceutical services executive and leadership consultant with more than 30 years of industry experience. She is currently the President and Chief Operating Officer for Novan, Inc., as well as a Managing Director for Habergeon LLC. Ms. Stafford retired in 2015 from her position as President of Clinical Development at Quintiles (now part of iQvia). Ms. Stafford’s global responsibilities encompassed Phase I-IV clinical research services and she served as a member of Quintiles Executive Committee. She was an Independent Director for BioImaging, later BioClinica (NASDAQ: BIOC), from 2002 to 2008. In addition, Ms. Stafford served as a member of the CDISC (Clinical Data Interchange Standards Consortium) Board of Directors for 9 years, serving as Chair for 2 years and as a member of the Executive Committee for 6 years. Ms. Stafford is an Adjunct Professor in Public Health Leadership for the UNC-CH Gillings School of Global Public Health and emeritus member of the UNC-CH Public Health Foundation Board. In 2011, Ms. Stafford received the Triangle Business Journal’s Women in Business Award. FierceBiotech named Ms. Stafford one of the 10 top women in biotech in 2012. Ms. Stafford holds a Bachelor of Science and a Master of Public Health in Biostatistics from the University of North Carolina at Chapel Hill. In 2016, the university honored Ms. Stafford with its Distinguished Alumna Award.

Chris Reinhard is a Chief Executive Officer at Activation Therapeutics Inc, Chief Executive Officer (formerly Collateral Therapeutics) at Angiogonetics Therapeutics, and Chief Executive Officer at LifeAgain Advanced Medical Data Analytics and is based in San Diego, California. He has worked as Managing Director & Vice President at Henley Group; Chief Executive Officer at InnerCool Therapeutics, Inc.; and Assistant Treasurer / Director Special Projects at Signal AI.

John Kollins is a President/CEO/Co-Founder at SATSUMA PHARMACEUTICALS INC, Board Member at SATSUMA PHARMACEUTICALS INC, and Advisor at Covx and is based in South San Francisco, California. He has experience at ATHENA NEUROSCIENCES INC and Elan Pharmaceutical and has worked as Chief Operating Officer at Oxigene Inc, Vice President at SurroMed, and Advisor To CEO at SurroMed. John works or has worked as Consultant at Covx, CHAIRMAN at CovX Research LLC, and Consultant at Entelos. He studied at Duke University between 1981 and 1985 and University of Virginia Darden School of Business between 1987 and 1989.

CEO of @EvofemBio. Founding CEO of @WCG_cares. Champion for women all over the world. Published author, keynote speaker and mother.